association between plasma beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease

background beta-2 microglobulin (b2m) is considered as a surrogate marker for middle molecule uremic toxins and a key component in dialysis-related amyloidosis. however, few studies have evaluated role of b2m in patients with chronic kidney disease (ckd). objectives the purpose of this study was to evaluate the association of plasma b2m level with some metabolic and cardiac performance factors in patients with ckd. patients and methods in this case-control study, we measured plasma b2m level in 86 patients with different stages of ckd and 78 age- and sex-matched individuals, as healthy control group. then we investigated the association between plasma b2m level and left ventricular hypertrophy, ejection fraction (ef), and left ventricular end-diastolic diameter (lvedd) in echocardiography and some inflammatory and metabolic factors in patients with ckd. results mean plasma b2m level was significantly higher in patients with ckd than in control group (p < 0.001). it was directly correlated with serum c-reactive protein (r = 0.167, p < 0.001), phosphate (r = 0.112, p < 0.001) levels, and left ventricular mass index (r = 0.438, p < 0.001) and lvedd (r = 0.275, p < 0.001) in echocardiography. it was also inversely correlated with glomerular filtration rate (r = -0.033, p < 0.001), albumin (r = -0.521, p < 0.001), hemoglobin (r = -0.748, p < 0.001), and ef (r = -0.625, p < 0.001). conclusions our findings suggested that plasma b2m level is inversely associated with gfr and ef and directly correlated with some metabolic and cardiac performance factors.